Content by Haplogen
Haplogen, a biotechnology company developing antiviral therapies, and CeMM, the Center for Molecular Medicine of the Austrian Academy of Sciences, today announced that they are making available their large collection of human cell lines that are deficient for single genes, which they have been building over the past three years as part of a public-private partnership.
| 3 min read
Page 1 of 1 - 1 Total Items
